Active Surveillance for Carbapenem-Resistant Enterobacterales (CRE) Colonization and Clinical Course of CRE Colonization among Hospitalized Patients at a University Hospital in Thailand
Abstract
:1. Introduction
2. Results
2.1. Study Population
2.2. Prevalence of CRE Colonization upon Admission
2.3. Comparison of Patients with and without CRE Colonization upon Admission
2.4. Acquisition of CRE during Hospitalization
2.5. Comparison of Patients with and without CRE Acquisition during Hospitalization among Patients without CRE Colonization upon Admission
2.6. Prevalence of CRE Fecal Carriage upon Admission and during Hospitalization Classified by Year during 2018–2021
2.7. Development of CRE Infection
2.8. CRE Colonization after Hospital Discharge
3. Discussion
4. Patients and Methods
Data Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gupta, N.; Limbago, B.M.; Patel, J.B.; Kallen, A.J. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin. Infect. Dis. 2011, 53, 60–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cantón, R.; Akóva, M.; Carmeli, Y.; Giske, C.G.; Glupczynski, Y.; Gniadkowski, M.; Livermore, D.M.; Miriagou, V.; Naas, T.; Rossolini, G.M.; et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2012, 18, 413–431. [Google Scholar] [CrossRef] [Green Version]
- Soontaros, S.; Leelakanok, N. Association between carbapenem-resistant Enterobacteriaceae and death: A systematic review and meta-analysis. Am. J. Infect. Control 2019, 47, 1200–1212. [Google Scholar] [CrossRef]
- Geffen, Y.; Finkelstein, R.; Oren, I.; Shalaginov, R.; Tavleva, I.; Sprecher, H. Changing epidemiology of carbapenem-resistant Enterobacteriaceae carriage during an outbreak of carbapenem-resistant Klebsiella pneumoniae. J. Hosp. Infect. 2010, 76, 355–356. [Google Scholar] [CrossRef]
- Prabaker, K.; Lin, M.Y.; McNally, M.; Cherabuddi, K.; Ahmed, S.; Norris, A.; Lolans, K.; Odeh, R.; Chundi, V.; Weinstein, R.A.; et al. Transfer from high-acuity long-term care facilities is associated with carriage of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae: A multihospital study. Infect. Control Hosp. Epidemiol. 2012, 33, 1193–1199. [Google Scholar] [CrossRef] [PubMed]
- Papadimitriou-Olivgeris, M.; Marangos, M.; Fligou, F.; Christofidou, M.; Bartzavali, C.; Anastassiou, E.D.; Filos, K.S. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J. Antimicrob. Chemother. 2012, 67, 2976–2981. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kelly, A.M.; Mathema, B.; Larson, E.L. Carbapenem-resistant Enterobacteriaceae in the community: A scoping review. Int. J. Antimicrob. Agents 2017, 50, 127–134. [Google Scholar] [CrossRef] [PubMed]
- Péus, D.; Newcomb, N.; Hofer, S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med. Inform. Decis. Mak. 2013, 13, 72. [Google Scholar] [CrossRef] [Green Version]
- National Antimicrobial Resistance Surveillance Center, Thailand (NARST). Antibiogram 2018. Available online: http://narst.dmsc.moph.go.th/ (accessed on 1 June 2022).
- Thongkoom, P.; Kanchanahareutai, S.; Chantrakooptungkul, S.; Rahule, S.; Pupan, M.; Tuntrakul, P.; Masan, N.; Teammongkolrat, L. Carbapenem-Resistant Enterobacteriaceae at Rajavithi Hospital: Results of a Microbiology Laboratory Program (2009–2015). J. Med. Assoc. Thai. 2017, 100 (Suppl. S1), S212–S221. [Google Scholar]
- Prakobsrikul, N.; Malathum, K.; Santanirand, P.; Chumnumwat, S.; Piebpien, P.; Montakantikul, P. Correlation between antimicrobial consumption and the prevalence of carbapenem-resistant Escherichia coli and carbapenem-resistant Klebsiella pneumoniae at a university hospital in Thailand. J. Clin. Pharm. Ther. 2019, 44, 292–299. [Google Scholar] [CrossRef]
- Netikul, T.; Kiratisin, P. Genetic Characterization of Carbapenem-Resistant Enterobacteriaceae and the Spread of Carbapenem-Resistant Klebsiella pneumonia ST340 at a University Hospital in Thailand. PLoS ONE 2015, 10, e0139116. [Google Scholar] [CrossRef]
- Chotiprasitsakul, D.; Srichatrapimuk, S.; Kirdlarp, S.; Pyden, A.D.; Santanirand, P. Epidemiology of carbapenem-resistant Enterobacteriaceae: A 5-year experience at a tertiary care hospital. Infect. Drug Resist. 2019, 12, 461–468. [Google Scholar] [CrossRef] [Green Version]
- Tängdén, T.; Giske, C.G. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: Clinical perspectives on detection, treatment and infection control. J. Intern. Med. 2015, 277, 501–512. [Google Scholar] [CrossRef]
- Nordmann, P.; Gniadkowski, M.; Giske, C.G.; Poirel, L.; Woodford, N.; Miriagou, V. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 2012, 18, 432–438. [Google Scholar] [CrossRef] [Green Version]
- García-Fernández, S.; Hernández-García, M.; Valverde, A.; Ruiz-Garbajosa, P.; Morosini, M.I.; Cantón, R. CHROMagar mSuperCARBA performance in carbapenem-resistant Enterobacteriaceae isolates characterized at molecular level and routine surveillance rectal swab specimens. Diagn. Microbiol. Infect. Dis. 2017, 87, 207–209. [Google Scholar] [CrossRef]
- Soria Segarra, C.; Larrea Vera, G.; Berrezueta Jara, M.; Arévalo Mendez, M.; Cujilema, P.; Serrano Lino, M.; Segarra, C.S. Utility of CHROMagar mSuperCARBA for surveillance cultures of carbapenemase-producing Enterobacteriaceae. New Microbes New Infect. 2018, 26, 42–48. [Google Scholar] [CrossRef]
- Okamoto, K.; Lin, M.Y.; Haverkate, M.; Lolans, K.; Moore, N.M.; Weiner, S.; Blom, D.; Rhee, Y.; Kemble, S.; Fogg, L.; et al. Modifiable Risk Factors for the Spread of Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Among Long-Term Acute-Care Hospital Patients. Infect. Control Hosp. Epidemiol. 2017, 38, 670–677. [Google Scholar] [CrossRef]
- Salomão, M.C.; Guimarães, T.; Duailibi, D.F.; Perondi, M.B.M.; Letaif, L.S.H.; Montal, A.C.; Rossi, F.; Cury, A.P.; Duarte, A.J.S.; Levin, A.S.; et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: Prevalence, risk factors, and acquisition rate. J. Hosp. Infect. 2017, 97, 241–246. [Google Scholar] [CrossRef] [PubMed]
- Salomão, M.C.; Freire, M.P.; Boszczowski, I.; Raymundo, S.F.; Guedes, A.R.; Levin, A.S. Increased Risk for Carbapenem-Resistant Enterobacteriaceae Colonization in Intensive Care Units after Hospitalization in Emergency Department. Emerg. Infect. Dis. 2020, 26, 1156–1163. [Google Scholar] [CrossRef]
- Gottesman, T.; Agmon, O.; Shwartz, O.; Dan, M. Household transmission of carbapenemase-producing Klebsiella pneumoniae. Emerg. Infect. Dis. 2008, 14, 859–860. [Google Scholar] [CrossRef] [PubMed]
- Van Hattem, J.M.; Arcilla, M.S.; Bootsma, M.C.; van Genderen, P.J.; Goorhuis, A.; Grobusch, M.P.; Molhoek, N.; Lashof, A.M.O.; Schultsz, C.; Stobberingh, E.E.; et al. Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiol. 2016, 11, 857–864. [Google Scholar] [CrossRef]
- Boonyasiri, A.; Tangkoskul, T.; Seenama, C.; Saiyarin, J.; Tiengrim, S.; Thamlikitkul, V. Prevalence of antibiotic resistant bacteria in healthy adults, foods, food animals, and the environment in selected areas in Thailand. Pathog. Glob. Health 2014, 108, 235–245. [Google Scholar] [CrossRef] [Green Version]
- Sudatip, D.; Tiengrim, S.; Chasiri, K.; Kritiyakan, A.; Phanprasit, W.; Morand, S.; Thamlikitkul, V. One Health Surveillance of Antimicrobial Resistance Phenotypes in Selected Communities in Thailand. Antibiotics 2022, 11, 556. [Google Scholar] [CrossRef] [PubMed]
- Thamlikitkul, V.; Tiengrim, S.; Thamthaweechok, N.; Buranapakdee, P.; Chiemchaisri, W. Contamination by Antibiotic-Resistant Bacteria in Selected Environment in Thailand. Int. J. Environ. Res. Public Health 2019, 16, 3753. [Google Scholar] [CrossRef] [Green Version]
- Tangkoskul, T.; Thamthaweechock, N.; Seenama, C.; Thamlikitkul, V. Antibiotic-Resistant Bacteria and Antibiotic Residue Contamination in Fresh Raw Foods Sold at Wholesale Markets in Thailand. J. Med. Assoc. Thai. 2021, 104, 1–9. [Google Scholar]
- Schimpff, S.C.; Young, V.M.; Greene, W.H.; Vermeulen, G.D.; Moody, M.R.; Wiernik, P.H. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann. Intern. Med. 1972, 77, 707–714. [Google Scholar] [CrossRef]
- Wingard, J.R.; Dick, J.; Charache, P.; Saral, R. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob. Agents Chemother. 1986, 30, 435–439. [Google Scholar] [CrossRef] [Green Version]
- Tancrède, C.H.; Andremont, A.O. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J. Infect. Dis. 1985, 152, 99–103. [Google Scholar] [CrossRef]
- Peña, C.; Pujol, M.; Ardanuy, C.; Ricart, A.; Pallares, R.; Liñares, J.; Ariza, J.; Gudiol, F. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 1998, 42, 53–58. [Google Scholar] [CrossRef] [Green Version]
- McConville, T.H.; Sullivan, S.B.; Gomez-Simmonds, A.; Whittier, S.; Uhlemann, A.C. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PLoS ONE 2017, 12, e0186195. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Wang, Q.; Yin, Y.; Chen, H.; Jin, L.; Gu, B.; Xie, L.; Yang, C.; Ma, X.; Li, H.; et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. Antimicrob. Agents Chemother. 2018, 62, e01882-17. [Google Scholar] [CrossRef] [PubMed]
Variables | CRE Colonization (N = 82) | No CRE Colonization (N = 446) | p Value |
---|---|---|---|
Male | 44 (53.7%) | 253 (56.7%) | 0.61 |
Mean age (SD), years | 67.0 (17.2) | 63.1 (18.1) | 0.07 |
Median Karnofsky score (range) | 60 (20–100) | 70 (20–100) | <0.001 |
Comorbid conditions | 78 (95.1%) | 428 (96.0%) | 0.76 |
Hypertension | 52 (63.4%) | 272 (61.0%) | 0.68 |
Diabetes mellitus | 29 (35.4%) | 176 (39.5%) | 0.48 |
Cardiovascular diseases | 28 (34.1%) | 152 (34.1%) | 0.99 |
Renal diseases | 26 (31.7%) | 139 (31.2%) | 0.92 |
Neurological diseases | 33 (40.2%) | 113 (25.3%) | 0.006 |
Gastrointestinal/hepatobiliary diseases | 19 (23.2%) | 89 (20.0%) | 0.51 |
Pulmonary diseases | 13 (15.9%) | 83 (18.6%) | 0.55 |
Solid malignancy | 14 (17.1%) | 79 (17.7%) | 0.89 |
Autoimmune diseases | 12 (14.6%) | 62 (13.9%) | 0.86 |
Hematological malignancy | 6 (7.3%) | 15 (3.4%) | 0.12 |
Solid organ transplant | 2 (2.4%) | 6 (1.3%) | 0.62 |
Previous healthcare exposure | |||
Medical procedure within 3 months | 55 (67.1%) | 252 (56.5%) | 0.08 |
Indwelling urinary catheter | 48 (58.5%) | 220 (49.3%) | 0.13 |
Nasogastric tube | 35 (42.7%) | 104 (23.3%) | <0.001 |
Endotracheal tube/tracheostomy tube | 19 (23.2%) | 39 (8.7%) | <0.001 |
Chronic dialysis | 6 (7.3%) | 28 (6.3%) | 0.73 |
Central venous catheterization | 10 (12.2%) | 16 (3.6%) | 0.003 |
Previous hospitalization within 3 months | 59 (72.0%) | 188 (42.2%) | <0.001 |
Use of immunosuppressive agents within 3 months | 19 (23.2%) | 100 (22.4%) | 0.88 |
Transfer from long-term care facility | 13 (15.9%) | 43 (9.6%) | 0.09 |
Major surgery within 3 months | 6 (7.3%) | 18 (4.0%) | 0.15 |
Use of antibiotics within 3 months | 71 (86.6%) | 298 (66.8%) | <0.001 |
Cephalosporins | 36 (43.9%) | 191 (42.8%) | 0.86 |
Beta-lactams/beta-lactamase inhibitors | 47 (57.3%) | 127 (28.5%) | <0.001 |
Macrolides | 9 (11.0%) | 81 (18.2%) | 0.11 |
Fluoroquinolones | 16 (19.5%) | 48 (10.8%) | 0.03 |
Carbapenems | 21 (25.6%) | 31 (7.0%) | <0.001 |
Penicillins | 6 (7.3%) | 26 (5.8%) | 0.62 |
Vancomycin | 11 (13.4%) | 10 (2.2%) | <0.001 |
Fosfomycin | 6 (7.3%) | 2 (0.4%) | <0.001 |
Aminoglycosides | 2 (2.4%) | 4 (0.9%) | 0.24 |
Colistin | 2 (2.4%) | 0 (0.0%) | 0.02 |
Previous CRE colonization | 11 (13.4%) | 4 (0.9%) | <0.001 |
Previous CRE infection | 6 (7.3%) | 0 (0.0%) | <0.001 |
Duration in observation room prior to hospitalization (range), days | 1 (0–5) | 0 (0–9) | 0.13 |
Median length of hospitalization (range), days | 12.5 (2–68) | 9 (1–177) | 0.008 |
All-cause mortality at hospital discharge | 19 (23.2%) | 69 (15.5%) | 0.09 |
Variables | Univariate Analysis OR (95% CI; p Value) | Multivariate Analysis OR (95% CI; p Value) |
---|---|---|
Median Karnofsky score (range) | 0.97 (0.96–0.99; p < 0.001) | |
Neurological diseases | 1.99 (1.22–3.24; p = 0.006) | |
Previous hospitalization within 3 months | 3.52 (2.10–5.91; p < 0.001) | 1.93 (1.06–3.49; p = 0.03) |
Use of beta-lactams/beta-lactamase inhibitors within 3 months | 3.37 (2.08–5.47; p < 0.001) | 2.10 (1.20–3.66; p = 0.009) |
Use of carbapenems within 3 months | 4.609 (2.49–8.53; p < 0.001) | 2.63 (1.29–5.35; p = 0.008) |
Use of fluoroquinolones within 3 months | 2.01 (1.08–3.75; p = 0.03) | |
Use of vancomycin within 3 months | 6.76 (2.77–16.49; p < 0.001) | |
Use of fosfomycin within 3 months | 17.53 (3.47–88.45; p = 0.001) | |
Previous CRE colonization | 17.12 (5.31–55.24; p < 0.001) | 6.95 (1.99–24.26; p = 0.002) |
Previous use of nasogastric tube | 2.45 (1.50–4.00; p < 0.001) | |
Previous use of endotracheal tube/tracheostomy tube | 3.15 (1.71–5.79; p < 0.001) | 2.49 (1.26–4.90; p = 0.008) |
Previous use of central venous catheterization | 3.73 (1.63–8.55; p = 0.002) |
Variables | CRE Colonization (N = 66) | No CRE Colonization (N = 167) | p Value |
---|---|---|---|
Antibiotic use during hospitalization | |||
Beta-lactams/beta-lactamase inhibitors | 39 (59.1%) | 87 (52.1%) | 0.33 |
Cephalosporins | 31 (47.0%) | 81 (48.5%) | 0.84 |
Carbapenems | 22 (33.3%) | 47 (28.1%) | 0.43 |
Fluoroquinolones | 14 (21.2%) | 33 (19.8%) | 0.80 |
Vancomycin | 13 (19.7%) | 22 (13.2%) | 0.21 |
Macrolide | 10 (15.2%) | 18 (10.8%) | 0.36 |
Colistin | 6 (9.1%) | 9 (5.4%) | 0.37 |
Penicillins | 5 (7.6%) | 11 (6.6%) | 0.78 |
Aminoglycosides | 3 (4.5%) | 2 (1.2%) | 0.14 |
Fosfomycin | 1 (1.5%) | 3 (1.8%) | 1.00 |
Procedure during hospitalization | |||
Indwelling urinary catheter | 49 (74.2%) | 117 (70.1%) | 0.53 |
Mechanical ventilator | 28 (42.4%) | 60 (35.9%) | 0.36 |
Central venous catheterization | 20 (30.3%) | 28 (16.8%) | 0.02 |
Surgery | 13 (19.7%) | 17 (10.2%) | 0.05 |
Principal diagnosis in this admission | |||
Pulmonary diseases | 18 (27.3%) | 46 (27.5%) | 0.97 |
Gastrointestinal/hepatic diseases | 9 (13.6%) | 28 (16.8%) | 0.56 |
Heart diseases | 9 (13.6%) | 21 (12.6%) | 0.83 |
Renal diseases | 6 (9.1%) | 18 (10.8%) | 0.70 |
Cerebrovascular diseases | 9 (13.6%) | 16 (9.6%) | 0.37 |
Solid malignancy | 5 (7.6%) | 12 (7.2%) | 1.00 |
Autoimmune diseases | 2 (3.0%) | 9 (5.4%) | 0.73 |
Hematological malignancy | 2 (9.0%) | 8 (4.8%) | 0.73 |
Diagnosis of infection during hospitalization | |||
Respiratory tract infection | 37 (56.1%) | 69 (41.3%) | 0.04 |
Urinary tract infection | 16 (24.2%) | 25 (15.1%) | 0.10 |
Gastrointestinal/hepatobiliary tract infection | 15 (22.7%) | 17 (10.2%) | 0.01 |
Bloodstream infection | 7 (10.6%) | 22 (13.2%) | 0.59 |
Skin and soft tissue infection | 5 (7.6%) | 23 (13.8%) | 0.19 |
Central nervous system infection | 2 (3.0%) | 4 (2.4%) | 0.68 |
Cardiovascular system infection | 1 (1.5%) | 0 (0.0%) | 0.29 |
Median length of hospitalization (range), days | 23.5 (3–177) | 13 (2–71) | <0.001 |
All-cause mortality at hospital discharge | 18 (27.3%) | 33 (19.8%) | 0.21 |
Variables | Univariate Analysis OR (95% CI; p Value) | Multivariate Analysis OR (95% CI; p Value) |
---|---|---|
Central venous catheterization | 2.16 (1.11–4.19; p = 0.02) | |
Surgery | 2.16 (0.99–4.76; p = 0.06) | 2.153 (0.95–4.87; p = 0.07) |
Respiratory tract infection | 1.81 (1.02–3.22; p = 0.04) | 2.05 (1.12–3.74; p = 0.02) |
Gastrointestinal/hepatobiliary tract infection | 2.60 (1.21–5.57; p = 0.01) | 2.99 (1.34–6.65; p = 0.007) |
Nov. to Dec. 2018 (N = 56) | Jan. to Dec. 2019 (N = 253) | Jan. to Dec. 2020 (N = 87) | Jan. to Dec. 2021 (N = 132) | |
---|---|---|---|---|
On admission | 3.6% | 15.4% | 13.8% | 22.0% |
During hospitalization | 29.6% | 25.5% | 16.7% | 24.5% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wangchinda, W.; Thamlikitkul, V.; Watcharasuwanseree, S.; Tangkoskul, T. Active Surveillance for Carbapenem-Resistant Enterobacterales (CRE) Colonization and Clinical Course of CRE Colonization among Hospitalized Patients at a University Hospital in Thailand. Antibiotics 2022, 11, 1401. https://doi.org/10.3390/antibiotics11101401
Wangchinda W, Thamlikitkul V, Watcharasuwanseree S, Tangkoskul T. Active Surveillance for Carbapenem-Resistant Enterobacterales (CRE) Colonization and Clinical Course of CRE Colonization among Hospitalized Patients at a University Hospital in Thailand. Antibiotics. 2022; 11(10):1401. https://doi.org/10.3390/antibiotics11101401
Chicago/Turabian StyleWangchinda, Walaiporn, Visanu Thamlikitkul, Sureerat Watcharasuwanseree, and Teerawit Tangkoskul. 2022. "Active Surveillance for Carbapenem-Resistant Enterobacterales (CRE) Colonization and Clinical Course of CRE Colonization among Hospitalized Patients at a University Hospital in Thailand" Antibiotics 11, no. 10: 1401. https://doi.org/10.3390/antibiotics11101401
APA StyleWangchinda, W., Thamlikitkul, V., Watcharasuwanseree, S., & Tangkoskul, T. (2022). Active Surveillance for Carbapenem-Resistant Enterobacterales (CRE) Colonization and Clinical Course of CRE Colonization among Hospitalized Patients at a University Hospital in Thailand. Antibiotics, 11(10), 1401. https://doi.org/10.3390/antibiotics11101401